⌘K
Loading ticker…
As of 2026-08-24, Spero Therapeutics, Inc. Common Stock (SPRO) has a 3-month relative strength percentile of 5 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 33. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.0%, relative volume 0.49×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
SPRO is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -27.6% / -46.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
SPRO is held by 2 ETFs as of May 2026. Top owner: QQQS at 0.53% weight, $101K notional.
Held by 7 ETFs · $4M across latest filings · largest weight 0.53% (QQQS).
Top 2 by value, from SEC N-PORT-P filings dated May 2026.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SPRO Jan avg: -3.13% median: -1.30% win: 50% σ: 10.65% n: 4 2022-04-12 → 2026-07-31 | SPRO Feb avg: -5.45% median: -5.18% win: 25% σ: 12.17% n: 4 2022-04-12 → 2026-07-31 | SPRO Mar avg: 0.72% median: 1.11% win: 50% σ: 6.65% n: 4 2022-04-12 → 2026-07-31 | SPRO Apr avg: -5.03% median: -8.61% win: 40% σ: 20.00% n: 5 2022-04-12 → 2026-07-31 | SPRO May avg: 43.05% median: 0.00% win: 60% σ: 136.93% n: 5 2022-04-12 → 2026-07-31 | SPRO Jun avg: -13.65% median: -16.67% win: 20% σ: 19.61% n: 5 2022-04-12 → 2026-07-31 | SPRO Jul avg: -9.47% median: -1.19% win: 40% σ: 24.46% n: 5 2022-04-12 → 2026-07-31 | SPRO Aug avg: -2.85% median: -5.41% win: 25% σ: 9.30% n: 4 2022-04-12 → 2026-07-31 (current) | SPRO Sep avg: 29.29% median: -5.68% win: 25% σ: 79.36% n: 4 2022-04-12 → 2026-07-31 | SPRO Oct avg: 2.08% median: -5.10% win: 25% σ: 18.49% n: 4 2022-04-12 → 2026-07-31 | SPRO Nov avg: -1.00% median: -1.13% win: 25% σ: 5.26% n: 4 2022-04-12 → 2026-07-31 | SPRO Dec avg: 1.39% median: -6.28% win: 25% σ: 18.70% n: 4 2022-04-12 → 2026-07-31 |